Study: Boston Scientific's Watchman heart implant bests warfarin

February 28, 2013 by Brad Perriello

Boston Scientific's Watchman heart implant scored better on quality-of-life measures than the anti-clotting drug warfarin after 1 year, according to a report in the Journal of the American College of Cardiology.

Boston Scientific's Watchman heart implant

The Watchman heart implant made by Boston Scientific (NYSE:BSX) improved quality-of-life measures more than warfarin in atrial fibrillation patients after 1 year, according to a study in the Journal of the American College of Cardiology.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp